MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

CirCode Biomed’s circular RNA drug HM2002 has received IND clearance from the FDA for the treatment of ischaemic heart ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

A new NDA was submitted in January 2024, which the FDA did accept, and that was later converted into a priority review. An ...

In the race to decarbonize the global economy, advanced materials are no longer a luxury – they’re a necessity.

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...

The EC has granted approval for the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) ...

Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting ...